Background: Hepatocellular carcinoma (HCC) is one of the most common primary hepatic
malignancies and growing challenges of global health. In this study, for the first time in Iran …

Background and Aims Survival data among patients with hepatitis C virus (HCV)‐related
hepatocellular carcinoma (HCC) after achieving sustained virologic response (SVR) with …

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related
death worldwide, with about 841,000 new cases and 782,000 deaths annually. Given the …

Background Most patients with hepatocellular carcinoma (HCC) are≥ 65 years old at
diagnosis and~ 20% present with disease amenable to curative intent surgical therapy. The …

Hepatocellular carcinoma (HCC) is one of the most prevalent and poorly responsive cancers
worldwide. Bromodomain and extraterminal (BET) inhibitors, such as JQ1 and OTX-015 …

Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related
deaths in the United States (US), with substantial disparities observed in cancer incidence …

Background Since the inception of the interferon‐free direct‐acting antiviral agents (DAAs)
for hepatitis C virus (HCV) infection, guidelines as to who should receive this potentially …

Abstract Background and Objectives Curative intent therapy is the standard of care for early‐
stage hepatocellular carcinoma (HCC). However, these therapies are under‐utilized, with …

Background Low socioeconomic status (SES) patients with early-stage hepatocellular
carcinoma (HCC) receive procedural treatments less often and have shorter survival. Little is …

Abstract Background: β-blockers (BBs) have shown promise in improving overall survival
(OS) in patients with breast, ovarian, pancreatic and lung cancer. However, few studies have …